Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15842273 | 0.82 | CA12 (0.75) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL30933370 | 0.79 | CA12 (1.00) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL3527681 | 0.79 | CA12 (1.00) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL2154447 | 0.78 | CA12 (0.69) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL27349181 | 0.76 | VKORC1 (0.52) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL24358817 | 0.76 | CA12 (0.67) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL14399066 | 0.76 | KDM4E (1.00) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL24199378 | 0.76 | CA12 (0.66) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL28844992 | 0.75 | CA12 (0.65) | CA12CA9MAPTKDM4EALDH1A1 | |
| SCHEMBL13315777 | 0.74 | CA12 (0.63) | CA12CA9MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124986-B1 | NITROCOUMARINS FOR DETECTING ALL MICRO-ORGANISMS | BIOMERIEUX SA (FR) | 2004-05-06 | — | — | EP | disclosed |
| US-6555332-B2 | Calibration using fluorescence signals | BIOMERIEUX S.A. (FR) | 2003-04-29 | — | — | US | disclosed |
| US-20020031795-A1 | Nitrocoumarins for detecting all micro-organisms | BIOMERIEUX S.A. (FR) | 2002-03-14 | — | — | US | disclosed |
| EP-1124986-A1 | NITROCOUMARINS FOR DETECTING ALL MICRO-ORGANISMS | Biomerieux S.A. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000028073-A1 | NITROCOUMARINS FOR DETECTING ALL MICRO-ORGANISMS | BIOMERIEUX S.A. (FR) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031795-A1 | Nitrocoumarins for detecting all micro-organisms | CBR3, CYB5R3, CBR1 | CA12 4339/4885CA9 3105/4885MAPT 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.